We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+65.49%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$2.65B
AUM Growth
+$969M
Cap. Flow
+$186M
Cap. Flow %
7.03%
Top 10 Hldgs %
54.64%
Holding
73
New
13
Increased
31
Reduced
10
Closed
12

Top Buys

1
IMVT icon
Immunovant
IMVT
+$49.6M
2
WVE icon
Wave Life Sciences
WVE
+$41.8M
3
QTTB icon
Q32 Bio
QTTB
+$30.2M
4
KRRO icon
Korro Bio
KRRO
+$20.3M
5
RLMD icon
Relmada Therapeutics
RLMD
+$20.2M

Top Sells

1
ACHN
Achillion Pharmaceuticals
ACHN
+$37.9M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$12.9M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$12M
4
QDEL icon
QuidelOrtho
QDEL
+$10.8M
5
QTNT
Quotient Limited Ordinary Shares
QTNT
+$9.95M

Sector Composition

1 Healthcare 94.97%
2 Communication Services 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
1
Rocket Pharmaceuticals
RCKT
$376M
$383M 14.44%
16,812,491
+225,000
+1% +$3.76M
ALNY icon
2
Alnylam Pharmaceuticals
ALNY
$35.7B
$189M 7.12%
1,637,864
-129,764
-7% -$12.9M
PTCT icon
3
PTC Therapeutics
PTCT
$6.52B
$184M 6.95%
3,832,480
+181,119
+5% +$7.7M
DRNA
4
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$129M 4.88%
5,874,229
-328,196
-5% -$6.6M
AXSM icon
5
Axsome Therapeutics
AXSM
$11.8B
$106M 4%
1,026,813
+180,692
+21% +$7.3M
BMY icon
6
Bristol-Myers Squibb
BMY
$124B
$105M 3.98%
1,642,951
+77,644
+5% +$4.45M
STOK icon
7
Stoke Therapeutics
STOK
$1.81B
$100M 3.79%
3,544,248
+188,782
+6% +$4.75M
QTTB icon
8
Q32 Bio
QTTB
$255M
$90M 3.4%
241,625
+105,543
+78% +$30.2M
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$83.2M 3.14%
645,427
+52,651
+9% +$5.08M
SRPT icon
10
Sarepta Therapeutics
SRPT
$1.82B
$78.2M 2.95%
605,762
-118,549
-16% -$12M
ADVM
11
DELISTED
Adverum Biotechnologies
ADVM
$73.6M 2.78%
638,661
+10,561
+2% +$931K
IMVT icon
12
Immunovant
IMVT
$8.27B
$66M 2.49%
+4,426,106
New +$49.6M
ZBH icon
13
Zimmer Biomet
ZBH
$17.6B
$65.5M 2.47%
450,507
+35,417
+9% +$4.89M
MIST icon
14
Milestone Pharmaceuticals
MIST
$148M
$63.4M 2.39%
3,958,264
+436,408
+12% +$7.72M
MASI
15
DELISTED
Masimo
MASI
$60.4M 2.28%
382,187
+11,032
+3% +$1.66M
ESTA icon
16
Establishment Labs
ESTA
$2.72B
$56.2M 2.12%
2,032,446
-7,235
-0.4% -$160K
MYOK
17
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$55.5M 2.09%
760,988
+35,963
+5% +$2.18M
VCEL icon
18
Vericel Corp
VCEL
$2.38B
$52M 1.96%
2,989,429
+343,953
+13% +$5.85M
PRQR icon
19
ProQR Therapeutics
PRQR
$240M
$47.4M 1.79%
4,779,135
+1,078,302
+29% +$8.4M
AXNX
20
DELISTED
Axonics, Inc. Common Stock
AXNX
$44.1M 1.66%
1,591,632
+57,027
+4% +$1.36M
ACHN
21
DELISTED
Achillion Pharmaceuticals
ACHN
$44.1M 1.66%
7,309,383
-6,555,000
-47% -$37.9M
BLU
22
DELISTED
BELLUS Health Inc.
BLU
$36.6M 1.38%
4,840,992
+662,836
+16% +$4.53M
AGEN
23
Agenus
AGEN
$209M
$36.1M 1.36%
452,252
-17,160
-4% -$1.15M
APYX icon
24
Apyx Medical
APYX
$180M
$28.7M 1.08%
3,391,279
+21,000
+0.6% +$152K
DMTK
25
DELISTED
DermTech, Inc. Common Stock
DMTK
$28.4M 1.07%
2,386,871
– –
1
2 3

Similar funds

BEI
Benjamin Edwards Inc Clayton, Missouri $10.1B AUM 14.03% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return

RTW Investments's Q4 2019 Portfolio in Review

As of Q4 2019, RTW Investments held 73 positions worth $2.65B, up 58% from $1.68B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

RTW Investments deployed $186M of net new capital in Q4 2019, opening 13 new positions and adding to 31 existing holdings. Its largest new stake was Immunovant: 4,426,106 shares worth $66M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Communication Services.

On the sell side, the largest reduction was Achillion Pharmaceuticals, an estimated $37.9M trimmed.

  • RTW Investments's largest Q4 2019 buy was Immunovant: 4,426,106 shares worth $66M.
  • RTW Investments added most to Q32 Bio in Q4 2019, an estimated $30.2M increase.
  • RTW Investments's biggest Q4 2019 reduction was Achillion Pharmaceuticals, cutting an estimated $37.9M.
  • RTW Investments fully exited QuidelOrtho in Q4 2019, selling an estimated $10.8M.
  • RTW Investments's ten largest holdings make up 55% of its $2.65B portfolio in Q4 2019.
  • RTW Investments opened 13 new positions and closed 12 in Q4 2019.
  • RTW Investments's portfolio value rose 58% quarter-over-quarter to $2.65B.

Based on RTW Investments's 13F filing for Q4 2019, filed 14 Feb 2020.